Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alkalinized lidocaine/heparin - Hyloris Pharmaceuticals/Vaneltix Pharma

Drug Profile

Alkalinized lidocaine/heparin - Hyloris Pharmaceuticals/Vaneltix Pharma

Alternative Names: Alenura; Alkalinized lidocaine HCl and heparin sodium; alkalinized lidocaine HCl/Heparin sodium; Heparin/alkalinized lidocaine - Hyloris Pharmaceuticals/Vaneltix Pharma; Lidocaine/heparin - Hyloris Pharmaceuticals/Vaneltix Pharma; VNX 004; VNX-001

Latest Information Update: 09 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaneltix Pharma
  • Developer Hyloris Pharmaceuticals; Vaneltix Pharma
  • Class Acetanilides; Analgesics; Anti-infectives; Anti-inflammatories; Antithrombotics; Class Ib antiarrhythmics; Heparins; Local anaesthetics; Mucolytics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Glycosaminoglycan stimulants; Heparanase inhibitors; Inflammation mediator inhibitors; Sodium channel antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Interstitial cystitis

Most Recent Events

  • 22 May 2023 Phase-II clinical trials in Interstitial cystitis in USA (Intravesicular) (NCT05737121)
  • 28 Feb 2023 Vaneltix Pharma plans a phase II trial for Pain in USA (Intravesicular) in March 2023 (NCT05737121)
  • 09 Mar 2022 Preclinical trials in Acute pain in USA (Topical) (Vaneltix Pharma pipeline, February 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top